Biomarkers Market by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.2.1              INCLUSIONS & EXCLUSIONS
1.3             MARKET SCOPE
1.3.1              MARKETS COVERED
・       FIGURE 1......................... BIOMARKERS MARKET SEGMENTATION
1.3.2              YEARS CONSIDERED IN THE REPORT
1.4             CURRENCY
1.5             LIMITATIONS
1.6             STAKEHOLDERS
1.7             SUMMARY OF CHANGES

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
・       FIGURE 2.................................................. RESEARCH DESIGN.. 36
2.1.1              SECONDARY DATA
2.1.2              PRIMARY DATA
・       FIGURE 3.................................................. PRIMARY SOURCES.. 38
・       FIGURE 4........ BIOMARKERS MARKET: BREAKDOWN OF PRIMARIES
2.1.2.1            KEY INDUSTRY INSIGHTS
2.2             MARKET SIZE ESTIMATION
・       FIGURE 5..... MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
・       FIGURE 6.... MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKERS PRODUCTS
・       FIGURE 7. BIOMARKERS MARKET: CAGR PROJECTIONS, 2021–2026
・       FIGURE 8... BIOMARKERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES
2.3             MARKET BREAKDOWN AND DATA TRIANGULATION
・       FIGURE 9.......................... DATA TRIANGULATION METHODOLOGY
2.4             RESEARCH LIMITATIONS
2.5             RESEARCH ASSUMPTIONS
2.6             RISK ANALYSIS

3.... EXECUTIVE SUMMARY

・       FIGURE 10........... BIOMARKERS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD BILLION)
・       FIGURE 11............... BIOMARKERS MARKET SHARE, BY TYPE, 2020
・       FIGURE 12........... BIOMARKERS MARKET, BY DISEASE INDICATION,
2021 VS. 2026 (USD BILLION)
・       FIGURE 13.... BIOMARKERS MARKET, BY APPLICATION, 2021−2026
・       FIGURE 14.......... GEOGRAPHICAL SNAPSHOT OF THE BIOMARKERS MARKET

4.... PREMIUM INSIGHTS

4.1             BIOMARKERS MARKET OVERVIEW
・       FIGURE 15................ THE GROWING IMPORTANCE OF COMPANION DIAGNOSTICS IS A KEY FACTOR EXPECTED TO DRIVE THE GROWTH OF THE BIOMARKERS MARKET
4.2             ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & COUNTRY (2020)
・       FIGURE 16 CONSUMABLES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3             EFFICACY BIOMARKERS MARKET, BY TYPE, 2020
・       FIGURE 17.. THE PREDICTIVE BIOMARKERS SEGMENT IS PROJECTED TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5.... MARKET OVERVIEW

5.1             MARKET DYNAMICS
・       FIGURE 18............. BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1              MARKET DRIVERS
5.1.1.1            THE GROWING IMPORTANCE OF COMPANION DIAGNOSTICS
・       TABLE 1...... RECENT DEVELOPMENTS IN COMPANION DIAGNOSTICS
5.1.1.2            INCREASING PREVALENCE OF CANCER WORLDWIDE
・       TABLE 2................... GLOBAL CANCER INCIDENCE, 2020 VS. 2040
・       TABLE 3 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
5.1.1.3            INCREASING FUNDS & GRANTS FOR BIOMARKER RESEARCH
5.1.1.4            CONTINUOUS PRODUCT INNOVATIONS
・       TABLE 4................................ PRODUCT LAUNCHES, 2018−2021
5.1.2              RESTRAINTS
5.1.2.1            HIGH CAPITAL INVESTMENTS AND LENGTHY TIMELINES FOR BIOMARKER DEVELOPMENT
・       TABLE 5................... TIMEFRAME FOR BIOMARKER DEVELOPMENT
5.1.3              OPPORTUNITIES
5.1.3.1            PERSONALIZED MEDICINE
・       FIGURE 19..... PERCENTAGE OF ONCOLOGY TRIALS INCORPORATING BIOMARKERS
・       TABLE 6........... BIOMARKERS OF CARDIOVASCULAR DISEASE (CVD)
5.1.3.2            EMERGING ECONOMIES
5.1.4              CHALLENGES
5.1.4.1            CHALLENGES ASSOCIATED WITH BIOMARKER VALIDATION
5.1.4.2            TECHNICAL ISSUES RELATED TO SAMPLE COLLECTION & STORAGE
5.2             IMPACT OF COVID-19 ON THE BIOMARKERS MARKET
5.3             REGULATORY ASSESSMENT
5.3.1              INTRODUCTION
5.3.2              BIOMARKER QUALIFICATION IN THE US
5.3.3              BIOMARKER QUALIFICATION IN THE EU
5.3.4              BIOMARKER ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US
5.3.5              METHOD: EMA APPROVALS
5.3.6              METHOD: FDA APPROVALS
5.3.7              COMPANION DIAGNOSTICS
5.4             VALUE CHAIN ANALYSIS
・       FIGURE 20............ BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
5.5             TECHNOLOGICAL ANALYSIS
5.5.1              IMMUNOASSAYS
5.5.1.1            IMMUNOHISTOCHEMISTRY (IHC)
5.5.1.2            FLOW CYTOMETRY
5.5.1.3            FLOW CYTOMETRY ELISA
5.5.2              NEXT-GENERATION SEQUENCING (NGS)
5.5.3              POLYMERASE CHAIN REACTION (PCR)
5.5.4              IN SITU HYBRIDIZATION
5.5.5              MICROARRAYS
5.5.6              MASS SPECTROMETRY. 71
5.6             PORTER’S FIVE FORCES ANALYSIS
・       TABLE 7... BIOMARKERS MARKET- PORTER’S FIVE FORCES ANALYSIS
5.6.1              COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.6.2              BARGAINING POWER OF SUPPLIERS
5.6.3              BARGAINING POWER OF BUYERS
5.6.4              THREAT OF SUBSTITUTES
5.6.5              THREAT OF NEW ENTRANTS
5.7             PATENT ANALYSIS
5.7.1              NUMBER OF PUBLICATIONS OVER LAST 10 YEARS
5.7.2              TOP 20 GRANTED PATENT OWNERS (US) IN LAST 20 YEARS
5.7.3              TOP 10 PLAYERS WITH HIGHEST NO. OF PATENT APPLICATIONS
5.7.4              LIST OF RECENT PATENTS
5.8             SUPPLY CHAIN ANALYSIS
・       FIGURE 21........... DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8.1              KEY INFLUENCERS
5.9             ECOSYSTEM ANALYSIS OF THE BIOMARKERS MARKET
・       FIGURE 22..... ECOSYSTEM ANALYSIS OF THE BIOMARKERS MARKET
5.9.1              ROLE IN THE ECOSYSTEM
5.10          Y.C., YCC SHIFT
・       FIGURE 23............... YC-YCC SHIFT FOR THE BIOMARKERS MARKET
5.11          RANGES/ SCENARIOS
・       FIGURE 24... DEPENDING ON HOW THE UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE BIOMARKERS MARKET – 2020

6.... BIOMARKERS MARKET, BY PRODUCT & SERVICE

6.1             INTRODUCTION
・       TABLE 8..... BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD BILLION)
6.2             CONSUMABLES
6.2.1              THE HIGHER FREQUENCY OF REPEATED PURCHASES OF CONSUMABLES TO DRIVE THE MARKET GROWTH
・       TABLE 9............ BIOMARKER CONSUMABLES MARKET, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 10 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 11.......... EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 12.... ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
6.3             SERVICES
6.3.1              THE GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES IS EXPECTED TO SUPPORT MARKET GROWTH
・       TABLE 13.. BIOMARKER SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 14...... NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 15.... EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 16........... ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
6.4             SOFTWARE
6.4.1              INCREASING ADOPTION OF BIOINFORMATICS TOOLS BY PHARMACEUTICAL COMPANIES TO SUPPORT THE MARKET GROWTH.. 84
・       TABLE 17 BIOMARKER SOFTWARE MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 18..... NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 19.. EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 20.......... ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD BILLION)

7.... BIOMARKERS MARKET, BY TYPE

7.1             INTRODUCTION
・       TABLE 21.......... BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
7.2             EFFICACY BIOMARKERS
・       TABLE 22..... EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 23 EFFICACY BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 24..... NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 25... EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 26.......... ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
7.2.1              PREDICTIVE BIOMARKERS
7.2.1.1            WIDE APPLICATIONS OF PREDICTIVE BIOMARKERS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS DRIVE THE GROWTH OF THIS SEGMENT
・       TABLE 27..... PREDICTIVE BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 28.. NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 29 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 30....... ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
7.2.2              SURROGATE BIOMARKERS
7.2.2.1            THE USE OF SURROGATE BIOMARKERS HELPS ACCELERATE DRUG DEVELOPMENT AND SHORTEN TIMELINES FOR REGULATORY APPROVAL
・       TABLE 31.... SURROGATE BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 32.. NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 33 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 34...... ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
7.2.3              PHARMACODYNAMIC BIOMARKERS
7.2.3.1            INCREASING UTILIZATION OF PHARMACODYNAMIC BIOMARKERS IN THE SELECTION & OPTIMIZATION OF DRUG DOSES SUPPORTS SEGMENT GROWTH
・       TABLE 35.. PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 36...... NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 37 . EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 38........... ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.2.4              PROGNOSTIC BIOMARKERS
7.2.4.1            PROGNOSTIC BIOMARKERS HELP IN PREDICTING THE RECURRENCE OF DISEASES.. 94
・       TABLE 39............ PROGNOSTIC BIOMARKERS MARKET, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 40 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 41........... EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 42..... ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
7.3             SAFETY BIOMARKERS
7.3.1              WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT IS EXPECTED TO FUEL MARKET GROWTH
・       TABLE 43... SAFETY BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 44........ NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 45..... EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 46 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
7.4             VALIDATION BIOMARKERS
7.4.1              VALIDATION BIOMARKERS ENABLE IN THE EVALUATION OF
DIAGNOSTIC SYSTEMS
・       TABLE 47.... VALIDATION BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 48.. NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 49 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 50....... ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)

8.... BIOMARKERS MARKET, BY DISEASE INDICATION

8.1             INTRODUCTION
・       TABLE 51... BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
8.2             CANCER
8.2.1              INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH & DIAGNOSIS IS EXPECTED TO DRIVE THE MARKET GROWTH
・       TABLE 52......... LIST OF FDA-APPROVED BIOMARKERS FOR CANCER
・       TABLE 53............ BIOMARKERS MARKET FOR CANCER, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 54. NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 55............ EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 56...... ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2019–2026 (USD BILLION)
8.2.2              SOLID BIOPSY
8.2.2.1            SOLID BIOPSY PROVIDES THE MUTATIONS FROM WITHIN THE TUMORS
8.2.3              LIQUID BIOPSY
8.2.3.1            A LIQUID BIOPSY HELPS DETECT CIRCULATING TUMOR CELLS
・       TABLE 57....... CANCER DISEASE INDICATION MARKET, BY TEST TYPE,
2019–2026 (USD BILLION)
8.3             INFECTIOUS DISEASES
8.3.1              THE INCREASING PREVALENCE OF INFECTIOUS DISEASES ARE EXPECTED TO INCREASE THE DEMAND FOR BIOMARKERS
・       TABLE 58...... BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 59. NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 60............ EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 61..... ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)
8.4             IMMUNOLOGICAL DISORDERS
8.4.1              INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE MARKET GROWTH
・       TABLE 62............ BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
・       TABLE 63 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 64................. NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 65..... EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 66...................... ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD BILLION)
8.5             NEUROLOGICAL DISORDERS
8.5.1              IMMUNOASSAYS ARE WIDELY USED IN THE DIAGNOSIS OF NEUROLOGICAL DISORDERS
・       TABLE 67.. BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 68................. NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 69....... EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 70. ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD BILLION)
8.6             CARDIOVASCULAR DISORDERS
8.6.1              THE INCREASING PREVALENCE OF CVD IS EXPECTED TO INCREASE THE DEMAND FOR CARDIAC BIOMARKERS.. 110
・       TABLE 71........... BIOMARKERS FOR CARDIOVASCULAR DISORDERS
・       TABLE 72............... BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 73................. NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 74... EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 75...................... ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
8.7             OTHER DISEASE INDICATIONS
・       TABLE 76.......................... BIOMARKERS FOR RENAL DISORDERS
・       TABLE 77......................................... ENDOCRINE BIOMARKERS
・       TABLE 78 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 79........ NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 80....... EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 81...... ASIA PACIFIC: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)

9.... BIOMARKERS MARKET, BY APPLICATION

9.1             INTRODUCTION
・       TABLE 82 BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
9.2             DIAGNOSTICS
9.2.1              THE INCREASING USE OF BIOMARKERS FOR THE DIAGNOSIS OF VARIOUS DISEASES TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
・       TABLE 83..... BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 84................. NORTH AMERICA: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 85..... EUROPE: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 86.. ASIA PACIFIC: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD BILLION)
9.3             DRUG DISCOVERY & DEVELOPMENT
9.3.1              BIOMARKERS PLAY A KEY ROLE AS BIOLOGICAL INDICATORS IN THE DEVELOPMENT OF NEW DRUGS
・       TABLE 87.............. BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 88......... NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 89.. EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 90............. ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD BILLION)
9.4             PERSONALIZED MEDICINE
9.4.1              INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE FOR TARGETED THERAPIES DRIVES THE MARKET GROWTH
・       TABLE 91............ SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS
・       TABLE 92. BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2019–2026 (USD BILLION)
・       TABLE 93................. NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 94....... EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 95. ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2019–2026 (USD BILLION)
9.5             DISEASE RISK ASSESSMENT
9.5.1              BIOMARKERS ARE WIDELY USED FOR THE CHARACTERIZATION OF TOXICITY IN DISEASE DIAGNOSIS & DRUG DEVELOPMENT PROCESSES
・       TABLE 96.. BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 97..... NORTH AMERICA: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 98......... EUROPE: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 99... ASIA PACIFIC: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT,
BY COUNTRY, 2019–2026 (USD BILLION)
9.6             OTHER APPLICATIONS
・       TABLE 100..... BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION,
2019–2026 (USD BILLION)
・       TABLE 101...... NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 102................. EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 103........... ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2019–2026 (USD BILLION)

10.. BIOMARKERS MARKET, BY REGION

10.1          INTRODUCTION
・       TABLE 104.... BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
10.2          NORTH AMERICA
・       FIGURE 25......................... NORTH AMERICA: MARKET SNAPSHOT
・       TABLE 105... NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 106.. NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT,
2019–2026 (USD BILLION)
・       TABLE 107......... NORTH AMERICA: BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 108.... NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 109................ NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 110..... NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.2.1            US
10.2.1.1          THE US IS EXPECTED TO DOMINATE THE BIOMARKERS MARKET IN NORTH AMERICA DURING THE FORECAST PERIOD
・       TABLE 111... US.: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 112... US: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 113..... US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 114 US: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 115...... US: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.2.2            CANADA
10.2.2.1          THE INCREASING INCIDENCE OF CANCER DRIVES THE GROWTH OF BIOMARKER RESEARCH IN CANADA
・       TABLE 116.... CANADA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 117... CANADA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 118....... CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 119........ CANADA: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 120............... CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.3          EUROPE
・       TABLE 121.... EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
・       TABLE 122.... EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 123.... EUROPE: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 124....... EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 125......... EUROPE: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 126 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.3.1            GERMANY
10.3.1.1          INCREASING GOVERNMENT FUNDING FOR BIOMARKER RESEARCH DRIVES THE MARKET GROWTH IN GERMANY
・       TABLE 127.. GERMANY: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 128. GERMANY: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 129..... GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 130...... GERMANY: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 131............. GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.3.2            UK
10.3.2.1          AVAILABILITY OF GOVERNMENT FUNDING AND STRATEGIC COLLABORATIONS WITH BIOTECH FIRMS HAVE SIGNIFICANTLY BOOSTED THE ADOPTION OF BIOMARKERS IN THE UK
・       TABLE 132.... UK: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 133... UK: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 134..... UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 135 UK: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 136...... UK: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.3.3            FRANCE
10.3.3.1          INCREASING GOVERNMENT INVESTMENTS IN GENOMICS & PROTEOMICS RESEARCH TO DRIVE THE MARKET GROWTH
・       TABLE 137.... FRANCE: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 138.... FRANCE: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 139....... FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 140......... FRANCE: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 141 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.3.4            REST OF EUROPE (ROE)
・       TABLE 142.. ROE: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 143. ROE: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 144... ROE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 145..... ROE: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 146.... ROE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.4          ASIA PACIFIC
・       FIGURE 26............................. ASIA PACIFIC: MARKET SNAPSHOT
・       TABLE 147........ ASIA PACFIC: BIOMARKERS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)
・       TABLE 148....... ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT,
2019–2026 (USD BILLION)
・       TABLE 149.... ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 150. ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 151.. ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 152......... ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.4.1            CHINA
10.4.1.1          THE INCREASING BURDEN OF DISEASES AND GROWING FOCUS ON THE DEVELOPMENT OF NOVEL DRUGS ARE EXPECTED TO DRIVE THE DEMAND FOR BIOMARKERS IN CHINA
・       TABLE 153 CHINA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 154...... CHINA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 155.......... CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 156.. CHINA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 157. CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.4.2            JAPAN
10.4.2.1          STRATEGIC COLLABORATIONS WITH LEADING PHARMACEUTICAL COMPANIES DRIVE THE MARKET GROWTH IN JAPAN
・       TABLE 158 JAPAN: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 159...... JAPAN: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 160.......... JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 161.. JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 162. JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.4.3            INDIA
10.4.3.1          THE GROWING PREVALENCE OF TARGET DISEASES IS EXPECTED TO SUPPORT THE BIOMARKERS MARKET IN INDIA
・       TABLE 163 INDIA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 164 INDIA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 165........... INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 166... INDIA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 167.. INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.4.4            REST OF ASIA PACIFIC (ROAPAC)
・       TABLE 168.... ROAPAC: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 169... ROAPAC: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 170....... ROAPAC: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 171......... ROAPAC: BIOMARKERS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)
・       TABLE 172................ ROAPAC: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.5          REST OF THE WORLD (ROW)
・       TABLE 173. ROW: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 174. ROW: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 175.. ROW: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 176.... ROW: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 177... ROW: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.5.1            LATIN AMERICA (LATAM)
10.5.1.1          AVAILABILITY OF RESEARCH FUNDING AND THE RISING AWARENESS OF ADVANCED SEQUENCING TECHNOLOGIES DRIVES THE MARKET GROWTH IN LATAM
・       TABLE 178...... LATAM: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 179..... LATAM: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 180......... LATAM: EFFICACY BIOMARKERS MARKET, BY TYPE,
2019–2026 (USD BILLION)
・       TABLE 181. LATAM: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 182. LATAM: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)
10.5.2            MIDDLE EAST AND AFRICA (MEA)
10.5.2.1          INCREASING FOCUS ON PROTEOMICS & GENOMICS RESEARCH SUPPORTS MARKET GROWTH IN THE MEA
・       TABLE 183.. MEA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
・       TABLE 184. MEA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 185... MEA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
・       TABLE 186.... MEA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
・       TABLE 187.... MEA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2019–2026 (USD BILLION)

11.. COMPETITIVE LANDSCAPE

11.1          KEY PLAYER STRATEGIES
11.1.1            OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOMARKERS PLAYERS
11.2          MARKET SHARE ANALYSIS
・       FIGURE 27 BIOMARKERS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2020
・       TABLE 188.......... BIOMARKERS MARKET: DEGREE OF COMPETITION
11.3          REVENUE ANALYSIS
・       FIGURE 28.. REVENUE ANALYSIS FOR KEY COMPANIES (2017-2020)
11.4          COMPANY EVALUATION QUADRANT
・       FIGURE 29. BIOMARKERS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2020
11.4.1            STAR
11.4.2            PERVASIVE
11.4.3            EMERGING LEADER.. 172
11.4.4            PARTICIPANT
11.5          COMPETITIVE LEADERSHIP MAPPING (START-UPS) (2020)
11.5.1            PROGRESSIVE COMPANIES
11.5.2            STARTING BLOCKS
11.5.3            DYNAMIC COMPANIES
11.5.4            RESPONSIVE COMPANIES
・       FIGURE 30....... COMPETITIVE LEADERSHIP MAPPING: BIOMARKERS MARKET
11.5.4.1          COMPETITIVE BENCHMARKING
・       TABLE 189......... COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
・       TABLE 190..... COMPANY APPLICATION FOOTPRINT (25 COMPANIES)
・       TABLE 191............ COMPANY REGION FOOTPRINT (25 COMPANIES)
・       TABLE 192....................... COMPANY FOOTPRINT (25 COMPANIES)
11.6          COMPETITIVE SCENARIO
11.6.1            PRODUCT LAUNCHES.. 180
・       TABLE 193.. BIOMARKERS MARKET: PRODUCT LAUNCHES, JANUARY 2018-MAY 2021
11.6.2            DEALS
・       TABLE 194 BIOMARKERS MARKET: DEALS, JANUARY 2018-MAY 2021
11.6.3            OTHERS

12.. COMPANY PROFILES

12.1          KEY COMPANIES
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS))*
12.1.1            F. HOFFMANN-LA ROCHE LTD
・       TABLE 195.......... HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
・       FIGURE 31 COMPANY SNAPSHOT: HOFFMANN-LA ROCHE LTD (2020)
・       TABLE 196.......... HOFFMANN-LA ROCHE LTD: PRODUCT OFFERINGS
・       TABLE 197........ HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS
12.1.2            THERMO FISHER SCIENTIFIC INC.
・       TABLE 198.. THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
・       FIGURE 32.. COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC INC (2020)
・       TABLE 199.... THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERINGS
・       TABLE 200 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
・       TABLE 201..................... THERMO FISHER SCIENTIFIC INC.: DEALS
・       TABLE 202................... THERMO FISHER SCIENTIFIC INC.: OTHERS
12.1.3            ABBOTT LABORATORIES
・       TABLE 203.............. ABBOTT LABORATORIES: BUSINESS OVERVIEW
・       FIGURE 33.... COMPANY SNAPSHOT: ABBOTT LABORATORIES (2020)
・       TABLE 204............. ABBOTT LABORATORIES: PRODUCT OFFERINGS
・       TABLE 205.............. ABBOTT LABORATORIES: PRODUCT LAUNCHES
12.1.4            QIAGEN N.V.
・       TABLE 206............................. QIAGEN N.V.: BUSINESS OVERVIEW
・       FIGURE 34................... COMPANY SNAPSHOT: QIAGEN N.V. (2020)
・       TABLE 207............... QIAGEN N.V.: PRODUCT/SERVICE OFFERINGS
・       TABLE 208............................. QIAGEN N.V.: PRODUCT LAUNCHES
・       TABLE 209................................................ QIAGEN N.V.: DEALS
12.1.5            PERKINELMER, INC. 204
・       TABLE 210................... PERKINELMER, INC.: BUSINESS OVERVIEW
・       FIGURE 35......... COMPANY SNAPSHOT: PERKINELMER, INC. (2020)
・       TABLE 211..... PERKINELMER, INC.: PRODUCT/SERVICE OFFERINGS
・       TABLE 212...................................... PERKINELMER, INC.: DEALS
12.1.6            MERCK KGAA
・       TABLE 213.......................... MERCK KGAA.: BUSINESS OVERVIEW
・       FIGURE 36................. COMPANY SNAPSHOT: MERCK KGAA (2020)
・       TABLE 214.............. MERCK KGAA: PRODUCT/SERVICE OFFERINGS
・       TABLE 215................................................ MERK KGAA: DEALS.. 210
・       TABLE 216............................................ MERCK KGAA: OTHERS
12.1.7            BIO-RAD LABORATORIES, INC.
・       TABLE 217...... BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
・       FIGURE 37..... COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2020)
・       TABLE 218..... BIO-RAD LABORATORIES, INC.: PRODUCT OFFERINGS
12.1.8            ENZO BIOCHEM, INC.
・       TABLE 219................. ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
・       FIGURE 38....... COMPANY SNAPSHOT: ENZO BIOCHEM, INC. (2020)
・       TABLE 220................. ENZO BIOCHEM, INC.: PRODUCT OFFERINGS
・       TABLE 221................................... ENZO BIOCHEM, INC.: OTHERS
12.1.9            CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
・       TABLE 222.... CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
・       FIGURE 39... COMPANY SNAPSHOT: CHARLES RIVER LABORATORIES
INTERNATIONAL, INC. (2020)
・       TABLE 223.... CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: SERVICE OFFERINGS
12.1.10         EUROFINS SCIENTIFIC
・       TABLE 224............... EUROFINS SCIENTIFIC.: BUSINESS OVERVIEW
・       FIGURE 40...... COMPANY SNAPSHOT: EUROFINS SCIENTIFIC (2020)
・       TABLE 225................. EUROFINS SCIENTIFIC: SERVICE OFFERINGS
12.1.11         MESO SCALE DIAGNOSTICS, LLC. 221
・       TABLE 226.. MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW
・       TABLE 227..... MESO SCALE DIAGNOSTICS, LLC: PRODUCT/SERVICE OFFERINGS
12.1.12         STRESSMARQ BIOSCIENCES INC. 222
・       TABLE 228.. STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
・       TABLE 229. STRESSMARQ BIOSCIENCES INC.: PRODUCT OFFERINGS
12.1.13         DIAMETRA
・       TABLE 230............................... DIAMETRA: BUSINESS OVERVIEW
・       TABLE 231.............................. DIAMETRA: PRODUCT OFFERINGS
12.1.14         SIGNOSIS, INC.
・       TABLE 232......................... SIGNOSIS, INC.: BUSINESS OVERVIEW
12.1.15         PRODUCTS OFFERED
・       TABLE 233........................ SIGNOSIS, INC.: PRODUCT OFFERINGS
12.2          OTHER COMPANIES
12.2.1            BIOMÉRIEUX SA
・       TABLE 234........................ BIOMÉRIEUX SA: COMPANY OVERVIEW
12.2.2            AXON MEDCHEM BV. 226
・       TABLE 235................... AXON MEDCHEM BV: COMPANY OVERVIEW
12.2.3            EKF DIAGNOSTICS HOLDINGS, PLC
・       TABLE 236 EKF DIAGNOSTICS HOLDINGS, PLC: COMPANY OVERVIEW
12.2.4            MICROCONSTANTS, INC.
・       TABLE 237............. MICROCONSTANTS, INC.: COMPANY OVERVIEW
12.2.5            NORTHEAST BIOANALYTICAL LABORATORIES LLC.
・       TABLE 238.......... NORTHEAST BIOANALYTICAL LABORATORIES LLC.: COMPANY OVERVIEW
12.2.6            Q2 SOLUTIONS LLC.. 228
・       TABLE 239.................... Q2 SOLUTIONS LLC: COMPANY OVERVIEW
12.2.7            JSR LIFE SCIENCES, LLC
・       TABLE 240.............. JSR LIFE SCIENCES, LLC: COMPANY OVERVIEW
12.2.8            BIOAGILYTIX LABS.. 229
・       TABLE 241..................... BIOAGILYTIX LABS.: COMPANY OVERVIEW
12.2.9            CELERION
・       TABLE 242................................ CELERION: COMPANY OVERVIEW
12.2.10         ANYGENES
・       TABLE 243............................... ANYGENES: COMPANY OVERVIEW
12.2.11         BIOMARKERBAY B.V
・       TABLE 244..... BIOMARKERBAY: COMPANY OVERVIEW
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS) MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

13.. APPENDIX

当レポートのプレスリリースは発行されておりません。